Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 10/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30755490 | 1.00 | TRPV3 (0.54) | TRPV3SCN9AKIF11LTA4HCHRNA7 | |
| SCHEMBL3721067 | 0.83 | TRPV3 (0.54) | TRPV3SCN9AKIF11LTA4H | |
| SCHEMBL27371412 | 0.83 | TRPV3 (0.54) | TRPV3SCN9AKIF11LTA4H | |
| SCHEMBL4592059 | 0.83 | TRPV3 (0.61) | TRPV3SCN9A | |
| SCHEMBL4592336 | 0.83 | TRPV3 (0.54) | TRPV3SCN9AKIF11LTA4H | |
| SCHEMBL4435179 | 0.78 | MEN1 (0.60) | TRPV3 | |
| SCHEMBL5650095 | 0.77 | SCN9A (0.46) | TRPV3SCN9AKIF11 | |
| SCHEMBL13680818 | 0.77 | TRPV3 (0.52) | TRPV3SCN9ACHRNA7 | |
| SCHEMBL28345610 | 0.77 | KIF11 (0.65) | TRPV3SCN9AKIF11 | |
| SCHEMBL787618 | 0.76 | SCN9A (0.58) | TRPV3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-7338960-B2 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1513526-B1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060089394-A1 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2006-04-27 | — | — | US | disclosed |
| CN-1674897-A | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as HPPAR activators | SMITHKLINE BEECHAM CORP (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1513526-A1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000315-A1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089394-A1 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators | LIPA, PNLIP, CEL | TRPV3 334/4885SCN9A 708/4885KIF11 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.